Drug intelligence / Profile preview

GLR2037

Development stage: Phase 1
Lead developer: Gan & Lee Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

GLR2037 is an investigational oral small molecule androgen receptor (AR) antagonist developed by Gan & Lee Pharmaceuticals. It is specifically designed for the treatment of advanced or metastatic prostate cancer, including cases that have progressed following standard endocrine therapy. By binding to the androgen receptor, GLR2037 inhibits the androgen-mediated signaling pathways that drive the proliferation and survival of prostate cancer cells. The drug is currently being evaluated in Phase I clinical trials to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with metastatic disease.

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on GLR2037.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLR2037.

Explore the full profile